These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1432 related articles for article (PubMed ID: 22900950)

  • 1. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
    Citrome L
    Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
    Bobo WV
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iloperidone, asenapine and lurasidone: a primer on their current status.
    Tarazi FI; Stahl SM
    Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
    Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
    J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.
    Greger J; Aladeen T; Lewandowski E; Wojcik R; Westphal E; Rainka M; Capote H
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):5-12. PubMed ID: 33177350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on newer antipsychotic drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Apr; 49(4):13-5. PubMed ID: 21446639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone for schizophrenia.
    Nussbaum A; Stroup TS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006369. PubMed ID: 18425951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.
    Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
    Clin Neuropharmacol; 2013; 36(6):223-38. PubMed ID: 24201235
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 72.